
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a Chatham, New Jersey-based clinical-stage biopharmaceutical company, announced on Wednesday the issuance of a patent that forms the basis for the company's developmental vaccine against monkeypox and smallpox.
According to the company, this patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.